Zobrazeno 31 - 40
of 260
pro vyhledávání: ''
Autor:
Ryuichi Ebisawa, Nobuyuki Yamamoto, Akira Inoue, Katsuyuki Kiura, Yoko Seki, Kunihiko Koboyashi, Takeshi Horai, Toyoaki Hida, Kazuto Nishio, Koji Takeda, Nobuyuki Katakami, Shinji Atagi, Yukito Ichinose, Koichi Goto, Mehdi Shahidi
Publikováno v:
Journal of Clinical Oncology. 31:3335-3341
Purpose New molecular targeted agents are needed for patients with non–small-cell lung cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. Afatinib, an oral irreversible ErbB family blocker, has preclinical activity in epider
Publikováno v:
Journal of Clinical Oncology. 33:e19-e21
Autor:
Julien Adam, David Planchard, Alexander Valent, Emma Pailler, Jean-Charles Soria, Fabrice Andre, Nathalie Auger, Melissa Taylor, Isabelle Borget, Amélie Barthelemy, Philippe Vielh, Marianne Oulhen, Benjamin Besse, Françoise Farace
Publikováno v:
Journal of Clinical Oncology. 31:2273-2281
Purpose The diagnostic test for ALK rearrangement in non–small-cell lung cancer (NSCLC) for crizotinib treatment is currently done on tumor biopsies or fine-needle aspirations. We evaluated whether ALK rearrangement diagnosis could be performed by
Autor:
Gilles Salles, Ama Z. S. Rohatiner, Jelle W. Kylstra, Hervé Tilly, Barbara Botto, Pierre Soubeyran, Achiel Van Hoof, Angelika Bischof-Delaloye, Franck Morschhauser, Anton Hagenbeek, Wim L.J. van Putten, John Radford
Publikováno v:
Journal of clinical oncology, 31(16), 1977-1983. American Society of Clinical Oncology
Purpose Updated results are presented after a median follow-up of 7.3 years from the phase III First-Line Indolent Trial of yttrium-90 (90Y) –ibritumomab tiuxetan in advanced-stage follicular lymphoma (FL) in first remission. Patients and Methods P
Autor:
Filip Janku, Johnique T. Atkins, Razelle Kurzrock, David S. Hong, Sarina Anne Piha-Paul, F.C. Holsinger, Apostolia Maria Tsimberidou
Publikováno v:
Journal of Clinical Oncology. 31:e137-e140
Autor:
William D. Travis, Prasad S. Adusumilli, Kyuichi Kadota, Jun-ichi Nitadori, Camelia S. Sima, Michel Sadelain, Valerie W. Rusch, Kei Suzuki
Publikováno v:
Journal of Clinical Oncology. 31:490-498
Purpose Mounting evidence suggests that tumor-infiltrating immune cells have prognostic value for patients with solid organ malignancies. Our aim was to investigate the prognostic significance of the immune microenvironment in patients with stage I l
Autor:
Kathryn S. Kolibaba, Barbara Grant, Raquel Izumi, Juthamas Sukbuntherng, Ahmed Hamdy, Nathan Fowler, Ranjana H. Advani, Betty Y. Chang, Richard R. Furman, Eric Hedrick, Thomas E. Boyd, Jeff P. Sharman, Joseph J. Buggy, Sara Rodriguez, Sonali M. Smith
Publikováno v:
Journal of Clinical Oncology. 31:88-94
Purpose Survival and progression of mature B-cell malignancies depend on signals from the B-cell antigen receptor, and Bruton tyrosine kinase (BTK) is a critical signaling kinase in this pathway. We evaluated ibrutinib (PCI-32765), a small-molecule i
Autor:
Frederick B. Hagemeister, Jorge E. Romaguera, Jeanette Marjorie Wood, Amanda Copeland, Larry W. Kwak, Kantharaj Ethirajulu, Joy Zhu, Sattva S. Neelapu, P. McLaughlin, Silvana de Castro Faria, Ramesh Jayaraman, Anas Younes, Michelle A. Fanale, Stefan Hart, Jatin P. Shah
Publikováno v:
Journal of Clinical Oncology. 30:4161-4167
Purpose The Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) pathway plays an important role in the pathogenesis of hematologic malignancies. We conducted a phase I dose-finding and pharmacokinetic/pharmacodynamic study o
Publikováno v:
Journal of Clinical Oncology. 30:2977-2980
Purpose To investigate whether suppression of plasma estradiol and estrone sulfate levels by the aromatase inhibitors (AIs) anastrozole and letrozole is related to body mass index (BMI) in postmenopausal women with early estrogen receptor (ER) –pos
Autor:
Sophie Abadie-Lacourtoisie, Claire Cropet, Jean-Marc Ferrero, Thomas Bachelot, Jean-Christophe Eymard, Isabelle Ray-Coquard, Eric Pujade-Lauraine, Gilles Freyer, Marc Debled, Céline Bourgier, Dominique Spaeth, D. Allouache, Eric Legouffe, Claude El Kouri
Publikováno v:
Journal of Clinical Oncology. 30:2718-2724
Purpose Cross-talk between signal transduction pathways likely contributes to hormone resistance in metastatic breast cancer (mBC). Everolimus, an oral inhibitor of the mammalian target of rapamycin, has restored sensitivity in endocrine-resistance m